What is Nuedexta's Price Without Insurance?
The list price for Nuedexta, a medication used to treat pseudobulbar affect (PBA), can vary significantly. Without insurance, a 30-day supply of Nuedexta can cost approximately $1,600 to $2,000 or more [1]. This high out-of-pocket cost is a common concern for individuals without prescription drug coverage.
Can I Get Help Paying for Nuedexta?
Several programs may offer financial assistance to patients struggling with the cost of Nuedexta. These can include manufacturer-sponsored discount programs, patient assistance foundations, and co-pay cards [2]. For example, the Nuedexta Patient Assistance Program offers free medication to eligible uninsured or underinsured patients [2]. Information on these programs can often be found on the drug manufacturer's website or through healthcare providers.
What is Pseudobulbar Affect (PBA)?
Pseudobulbar affect is a neurological condition characterized by involuntary episodes of laughing or crying that are disproportionate or unrelated to what the person is feeling [1]. It can occur in individuals with underlying neurological diseases or injuries, such as stroke, ALS, multiple sclerosis, or traumatic brain injury [1].
How Does Nuedexta Work?
Nuedexta's active ingredients are dextromethorphan hydrobromide and quinidine sulfate [1]. Quinidine is thought to inhibit the metabolism of dextromethorphan, increasing its levels in the body [1]. While the exact mechanism by which this combination treats PBA is not fully understood, it is believed to affect nerve pathways in the brain that control emotional expression [1].
When Did Nuedexta Become Available?
Nuedexta was approved by the U.S. Food and Drug Administration (FDA) in October 2010 [3].
What Are the Potential Side Effects of Nuedexta?
Common side effects of Nuedexta can include dizziness, drowsiness, diarrhea, cough, vomiting, and urinary tract infection [1]. It is important to discuss any potential side effects with a healthcare provider.
Are There Any Alternatives to Nuedexta for PBA?
While Nuedexta is a specific FDA-approved treatment for PBA, some off-label treatments and behavioral therapies may also be considered by healthcare providers, depending on the individual's condition and medical history [1]. The efficacy and safety of these alternatives can vary.
What is the Patent Status of Nuedexta?
Drug patents grant market exclusivity for a period. Information regarding Nuedexta's patent status and potential patent expiry dates can be found through resources that track pharmaceutical patents [4]. Patents typically last for 20 years from the filing date, though extensions and other factors can influence the actual market exclusivity period [4].
Who Manufactures Nuedexta?
Nuedexta is manufactured by Avanir Pharmaceuticals [1].
How is Nuedexta Different from Other PBA Treatments?
Nuedexta is the first and only FDA-approved medication specifically indicated for the treatment of PBA [1]. Its unique combination of dextromethorphan and quinidine targets the neurological pathways thought to be involved in PBA [1].
---
1. DrugPatentWatch.com
2. Nuedexta Patient Assistance Program Information
3. FDA Approval Information for Nuedexta
4. Pharmaceutical Patent Databases